Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K)

By Watanabe I.   Hagiwara Y.   Kadowaki S.-e.   Yoshikawa T.   Komase K.   Aizawa C.   Kiyono H.   Takeda Y.   McGhee J.R.   Chiba J.   Sata T.   Kurata T.   Tamura S.-i.  

Vaccine, Vol. 20, Iss. 29, 2002-10 ,pp. : 3443-3455

Elsevier

Access to resources Recommend Favorite

Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine

By Hagiwara Y.   Komase K.   Chen Z.   Matsuo K.   Suzuki Y.   Aizawa C.   Kurata T.   Tamura S.-i.  

Vaccine, Vol. 17, Iss. 22, 1999-07 ,pp. : 2918-2926

Elsevier

Access to resources Recommend Favorite

Oral administration of a bacterial immunomodulator enhances the immune response to cholera toxin

By Flo J.   Goldman H.   Roux M.E.   Massouh E.  

Vaccine, Vol. 14, Iss. 12, 1996-08 ,pp. : 1167-1173

Elsevier

Access to resources Recommend Favorite

Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin)

By Matsuo K.   Yoshikawa T.   Asanuma H.   Iwasaki T.   Hagiwara Y.   Chen Z.   Kadowaki S.-e.   Tsujimoto H.   Kurata T.   Tamura S.-i.  

Vaccine, Vol. 18, Iss. 24, 2000-06 ,pp. : 2713-2722

Elsevier

Access to resources Recommend Favorite

Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin

By Sheoran A.S.   Artiushin S.   Timoney J.F.  

Vaccine, Vol. 20, Iss. 11, 2002-02 ,pp. : 1653-1659

Elsevier

Access to resources Recommend Favorite